Evaluation of CD86 rs17281995Gene Polymorphism in Gastric and Intestinal Cancer Subjects in Tehran and Khorramabad Cities

Document Type : Research Articles

Authors

• Masoumeh Aalipour ¹
• Asghar Aalipour ²
• Mohammad Mousaei Ghasroldasht ¹

¹ Department of Genetics, Faculty of Biological Sciences and Technology, Shiahid Ashrafi Esfahani, Esfahan, Iran

² Department of Pathology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

https://doi.org/10.22067/jcmr.2022.76904.1040

Abstract

Colorectal cancer (CRC) and gastric cancer (GC) are multifactorial diseases likely influenced by genetic susceptibility. Gastric cancer is also the fourth most common cancer in the world and the second leading cause of cancer-related mortality. CD86 (B7-2) is a costimulatory molecule found on antigen-presenting cells (APCs) that is important in autoimmune, transplantation, and tumor immunity. This protein is expressed in the immune system cells and is involved in the pathogenesis of various inflammatory disorders and inflammation. Rs17281995 polymorphism is located in section 3’ UTR, and given the regulatory role of 3' UTR gene sequences, SNPs located in these regions can affect the expression and function of the corresponding protein. In the present study, the relationship between rs17281995 polymorphism located in the 3' UTR regulatory region of the CD86 gene sequence and the risk of colorectal and gastric cancer in Iranian patients was analyzed. Polymorphism was identified in 26 patients with colorectal cancer, 30 patients with gastric cancer, and 36 healthy controls using the high-resolution DNA melting curve analysis (HRM) technique. The Data was then analyzed using SPSS software. There was no significant relationship between rs17281995 polymorphism and colorectal (P = 0.75) and gastric cancers (P = 0.97) in the Iranian population. In addition, genotypic distribution analysis showed no significant difference between the patient and control groups (P˃0.05). Among people with colorectal cancer, 0.577 had the G allele and 0.423 had the C allele. In the control group, 0.639 had the G allele and 0.361 had the C allele. In conclusion, our data indicate that the CD86 rs17281995 gene polymorphism does not seem to be a risk factor for colorectal and gastric cancers in the Iranian population.

Keywords

• Polymorphism
• CD86
• HRM
• rs17281995
• SNP

20.1001.1.20089147.2022.14.1.5.5

References

Arani, S.H. and Kerachian, M.A. (2017) Rising rates of colorectal cancer among younger Iranians: is diet to blame?. Current  Oncololgy 24(2):131-137.

Arisawa, T., Tahara, T., Shibata, T., Nagasaka, M., Nakamura, M., Kamiya, Y., et al. (2007) Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia. International journal of molecular medicine 20(5): 717-723.

Azimzadeh, P., Romani, S., Mirtalebi, H., Fatemi, S.R., Kazemian, S., Khanyaghma, M., et al. (2013) Association of co-stimulatory human B-lymphocyte antigen B7-2 (CD86) gene polymorphism with colorectal cancer risk. Gastroenterology and Hepatology from Bed to Bench 6(2): 86.

Canedo, P., Durães, C., Pereira, F., Regalo, G., Lunet, N., Barros, H., et al. (2008) Tumor necrosis factor alpha extended haplotypes and risk of gastric carcinoma. Cancer Epidemiology, Biomarkers & Prevvention 17(9): 2416-2420.

Di Pasqua, A.J., Wallner, S., Kerwood, D.J. and Dabrowiak, J.C. (2009) Adsorption of the PtII anticancer drug carboplatin by mesoporous silica. Chemistry & Biodiversity 6(9): 1343-1349.

Fang, S.H., Efron, J.E., Berho, M.E. and Wexner, S.D., (2014) Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. Journal of the American College of Surgeons 219(5): 1056-1069.

Forat-Yazdi, M., Gholi-Nataj, M., Neamatzadeh, H., Nourbakhsh, P. and Shaker-Ardakani, H. (2015) Association of XRCC1 Arg399Gln polymorphism with colorectal cancer risk: a HuGE meta analysis of 35 studies. Asian Pacific Journal of Cancer Prevention 16(8): 3285-3291.

Geng, P., Zhao, X., Xiang, L., Liao, Y., Wang, N., Ou, J., et al. (2014) Distinct role of CD86 polymorphisms (rs1129055, rs17281995) in risk of cancer: evidence from a meta-analysis. Plos one 9(11): e109131.

González, C.A., Sala, N. and Capellá, G. (2002) Genetic susceptibility and gastric cancer risk. International Journal of Cancer 100(3): 249-260.

Hu, J.Y., Wang, S., Zhu, J.G., Zhou, G.H. and Sun, Q.B. (1999) Expression of B7 costimulation molecules by colorectal cancer cells reducestumorigenicity and induces anti-tumor immunity. World Journal of Gastroenterology 5(2): 147.

Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. A Cancer Journal for Clinicians 61(2):69-90.

Koido, S., Ohkusa, T., Homma, S., Namiki, Y., Takakura, K., Saito, K., et al. (2013) Immunotherapy for colorectal cancer. World journal of gastroenterology: World Journal of Gastroenterology 19(46): 8531.

Landi, D., Gemignani, F., Naccarati, A., Pardini, B., Vodicka, P., Vodickova, L., et al. (2008) Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29(3): 579-584.

Lenschow, D.J., Walunas, T.L. and Bluestone, J.A. (1996) CD28/B7 system of T cell costimulation. Annul Review of Immunology 14(1): 233-258.

Machado, J.C., Figueiredo, C., Canedo, P., Pharoah, P., Carvalho, R., Nabais, S., et al. (2003) A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 125(2): 364-371.

Milne, A.N., Carneiro, F., O’morain, C. and Offerhaus, G.J.A. (2009) Nature meets nurture: molecular genetics of gastric cancer. Human Genetic 126(5): 615-628.

Namazi, A., Forat-Yazdi, M., Jafari, M.A., Foroughi, E., Farahnak, S., Nasiri, R., et al. (2017) Association between polymorphisms of ERCC5 gene and susceptibility to gastric cancer: A systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention 18(10): 2611.

Namazi, A., Forat-Yazdi, M., Jafari, M., Farahnak, S., Nasiri, R., Foroughi, E., et al. (2018) Association of interleukin-10-1082 A/G (rs1800896) polymorphism with susceptibility to gastric cancer: meta-analysis of 6,101 cases and 8,557 controls. Arq Gastroenterol 55: 33-40.

Ohtani, H. (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer immunology 7(1).

Poorolajal, J., Moradi, L., Mohammadi, Y., Cheraghi, Z. and Gohari-Ensaf, F. (2020) Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiology and health 42.

Saeki, N., Saito, A., Choi, I.J., Matsuo, K., Ohnami, S., Totsuka, H., et al. (2011) A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology 140(3): 892-902.

Shademan, B., Masjedi, S., Karamad, V., Isazadeh, A., Sogutlu, F. and Nourazarian, A. (2022) CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges. Biochemical Genetics 1-25.

van der Merwe, P.A., Bodian, D.L., Daenke, S., Linsley, P. and Davis, S.J. (1997) CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. Journal of Experimental Medicine 185(3) : 393-404.

Wu, X., Zeng, Z., Chen, B., Yu, J., Xue, L., Hao, Y., et al. (2010) Association between polymorphisms in interleukin‐17A and interleukin‐17F genes and risks of gastric cancer. International  Journal of Cancer 127(1): 86-92.

Yin, M., Hu, Z., Tan, D., Ajani, J.A. and Wei, Q. (2009) Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. American Journal of Translational Research 1(1): 44.

Zhuang, W., Wu, X.T., Zhou, Y., Liu, L., Liu, G.J., Wu, T.X., et al. (2010) Interleukin10-592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Digestive Diseases and Sciences 55(6): 1525-1532.